Drug Database
Back to search

Netherlands· NL-032537382d14

Riamet 20 mg/120 mg, tabletten

A artemether and lumefantrine product containing artemether + lumefantrine, registered in Netherlands by Novartis Pharma B.V.. The same ATC class is registered in 7 of our 19 countries.

ATC P01BF01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedRiamet 20 mg/120 mg, tablettenATCP01BF01REGISTER NO.NL-032537382d14PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about artemether + lumefantrineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Artemether and lumefantrine is registered in 7 of 19 countries.

Countries holding a registration under ATC P01BF01 (artemether and lumefantrine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search artemether and lumefantrine products by name

Artemether and lumefantrine · ATC P01BF01

7 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of artemether and lumefantrine costs, country by country.

Normalised to the WHO defined daily dose (0.28 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Artemether and lumefantrine · price per daily dose (0.28 g)

USD · FX 28 Sept 2026

  • CH Switzerland$19.10
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ARTEMETHER + LUMEFANTRINE
Manufacturer
Novartis Pharma B.V.
Country
Netherlands (NL)
ATC code
P01BF01
ATC class
Artemether and lumefantrine
Defined daily dose
0.28 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    25773

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for artemether and lumefantrine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check artemether and lumefantrine against other medicinesHow interaction checks work

Artemether and lumefantrine · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Artemether and lumefantrine in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All artemether and lumefantrine products

Authorised across Europe · EMA

The same active substance is authorised in 7 EEA countries. Names it is sold under:

  • Austria · Riamet
  • Belgium · Riamet
  • Germany · Riamet
  • France · Riamet
  • United Kingdom (Northern Ireland) · Riamet
  • Portugal · Airalam, Artemeter + Lumefantrina Phagecon
  • Sweden · Riamet

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9cec995f-d7b2-4f91-a0f3-439cf03381be
GET /v1/drugs/9cec995f-d7b2-4f91-a0f3-439cf03381be?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h25773_smpc.pdf",
  "strength": null,
  "atc_label": "Artemether and lumefantrine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg25773",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROMELLOSE (E 464)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYSORBAAT 80 (E 433)",
    "SILICIUMDIOXIDE (E 551)"
  ],
  "substances": [
    "ARTEMETHER",
    "LUMEFANTRINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h25773.pdf",
  "authorised_at": "2001/01/23",
  "procedure_number": "SE/H/1778/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "25773",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about artemether and lumefantrine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console